USA flag logo/image

An Official Website of the United States Government

A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71143
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI058326
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
EPIVAX, INC.
146 CLIFFORD STREET PROVIDENCE, RI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
Agency: HHS
Contract: 1R43AI058326-01A1
Award Amount: $831,922.00
 

Abstract:

DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a rapid approach to the development of a tularemia vaccine that could be for BioDefense. First, F. tularensis genes that encode transmembrane, heat shock and secreted proteins will be screened for immunodominant epitopes by computer-driven (EpiMatrix) analysis of the bacterial genome. Limited in vitro assays will be performed to confirm MHC binding and immunogenicity of representative epitopes. Second, selected epitopes will be aligned and reverse translated in a string-of-beads formation into a DNA construct. The string of beads epitope construct will then be cloned into DNA plasmids optimized for strong and sustained expression in vivo. Third, we will vaccinate HLA-transgenic mice with the DNA vaccine constructs. De novo immune responses to the DNA vaccine constructs will be evaluated using intracellular cytokine flow cytometry. Fourth, we develop a model of protective immunity to aerosolized F. tularensis. Initially we will use this model to benchmark the protective efficacy of the LVS vaccine for later comparison studies. EpiVax will be responsible for selecting the F. tularensis epitopes and managing the project. The TB/HIV Research Lab at Brown University (subcontractor) will develop the oligonucleotide multi-epitope DNA vaccine constructs consisting of strings of the selected epitopes and Dr. Stephen Gregory (subcontractor, Liver Research Center, Lifespan Hospital) will perform the vaccination studies. The final product of Phase I will be an evaluation of the immunogenicity of several prototype tularemia vaccine constructs in transgenic mice and a functional challenge model. In Phase II we would screen additional epitopes, perform F. tularensis challenge studies, build the final vaccine constructs, optimize the immunogenicity of the final vaccine constructs with adjuvants and delivery vehicles and address the safety, toxicity and immunogenicity of the constructs in human subjects.

Principal Investigator:

Anne S. Degroot
4012773654
ANNE_DEGROOT@BROWN.EDU

Business Contact:

Ronita Fisher
4012722123
FISHERR@EPIVAX.COM
Small Business Information at Submission:

EPIVAX, INC.
EPIVAX, INC. 16 BASSETT ST PROVIDENCE, RI 02903

EIN/Tax ID: 050499380
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No